- KR₩16tn
- KR₩15tn
- KR₩216bn
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
Brief: Alteogen To Invest 253 Billion Won In Construction Of New Factory
Brief: Alteogen Q2 Operating. Profit 34.2 Billion Won
Brief: Alteogen - Signs Exclusive License Agreement For Alt-B4 Recombinant Human Hyaluronidase
Brief: Alteogen To Offer 16 Million Bonus Shares
Brief: Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics
Brief: Alteogen Signs Licensing Deal With Biogen International For Alt-B4
Brief: Alteogen 2025 Operating Profit 115 Billion Won, Up 275% From Year Earlier
Brief: Alteogen Signs $285 Million Contract With Gsk Unit
Brief: Alteogen Receives Positive CHMP Opinion For Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'
Refile: Merck plans to launch US subcutaneous version of Keytruda on October 1
Merck says Keytruda injection on par with approved IV version in trial
Brief: Alteogen Receives Ministry Of Food And Drug Safety Approval For Tergase®
Brief: Alteogen says its Drug Tergase Shows Excellent Immunogenicity Profile
Brief: Altos Biologics Completes Patient Enrollment In Global Phase 3 Clinical Trial Of Eylea
Brief: Alteogen Announces Completion Of Phase 1 Clinical Trial Of Aflibercept Biosimilar In Wet AMD Patients
Brief: Alteogen Enters Into Global License Agreement With A Top Pharmaceutical Company For Use Of Its Hybrozyme Technology
Brief: Alteogen's Gastric Cancer Drug Gets FDA Approval For Orphan Drug Designation
Brief: Alteogen receives China patent